We’re happy to showcase a collaboration just published in OncoImmunology. Since 2016, French biotech Exeliom Bioscience has been advancing therapeutic programs targeting the gut microbiota in Crohn’s disease and various types of cancer, based on the immuno-modulatory bacterium Faecalibacterium prausnitzii (oral drug EXL01). In this paper, we supported Exeliom Bioscience in the generation of in vivo and vitro data to decipher the mechanism of action of EXL01.

The in vivo study, based on the MCA205 syngeneic tumor model, demonstrates that oral supplementation with EXL1 restores the efficacy of anti-PD-L1 immunotherapy in animals with antibiotics-induced gut dysbiosis. The subsequent in vitro investigation, based on the MLR assay, showed that the EXL1 strain boosts the activation of both dendritic cells and T cells in the presence of anti-PD-L1 antibody.

Read the paper

WordPress Lightbox